Difference between revisions of "Ixabepilone (Ixempra)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 4: | Line 4: | ||
<br>Extravasation: [[irritant]] | <br>Extravasation: [[irritant]] | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 11: | Line 11: | ||
==Patient drug information== | ==Patient drug information== | ||
*[https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022065s006lbl.pdf#page=31 Ixabepilone (Ixempra) patient drug information]<ref>[http://packageinserts.bms.com/pi/pi_ixempra.pdf#page=8 Ixabepilone (Ixempra) patient drug information]</ref> | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022065s006lbl.pdf#page=31 Ixabepilone (Ixempra) patient drug information]<ref>[http://packageinserts.bms.com/pi/pi_ixempra.pdf#page=8 Ixabepilone (Ixempra) patient drug information]</ref> | ||
| − | *[https://chemocare.com/ | + | *[https://chemocare.com/druginfo/ixabepilone.aspx Ixabepilone (Ixempra) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/ixabepilone.aspx Ixabepilone (Ixempra) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/ixabepilone-patient-drug-information Ixabepilone (Ixempra) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ixabepilone-patient-drug-information Ixabepilone (Ixempra) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/ixabepilone-patient-drug-information Ixabepilone (Ixempra) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ixabepilone-patient-drug-information Ixabepilone (Ixempra) patient drug information (UpToDate)]</ref> | ||
Latest revision as of 01:00, 29 June 2024
General information
Class/mechanism: Microtubule inhibitor; semi-synthetic analog of epothilone B. Ixabepilone binds to beta tubulin on microtubules, suppresses the dynamic instability of alpha beta II and alpha beta III, and disrupts normal microtubule dynamics. This results in arrest in the mitotic phase of the cell cycle and cell death.[1][2][3]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Ixabepilone (Ixempra) patient drug information[4]
- Ixabepilone (Ixempra) patient drug information (Chemocare)[5]
- Ixabepilone (Ixempra) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 2007-10-16: Initial approval in combination with capecitabine for the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline and a taxane. (Based on CA163-046 & CA163-048)
- 2007-10-16: Initial approval as monotherapy for the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline, a taxane, and capecitabine. (Based on CA163-081)
Also known as
- Code name: BMS-247550
- Generic names: azaepothilone B, epothilone B lactam
- Brand name: Ixempra
References
- ↑ 1.0 1.1 Ixabepilone (Ixempra) package insert
- ↑ Ixabepilone (Ixempra) package insert (locally hosted backup)
- ↑ Ixempra manufacturer's site
- ↑ Ixabepilone (Ixempra) patient drug information
- ↑ Ixabepilone (Ixempra) patient drug information (Chemocare)
- ↑ Ixabepilone (Ixempra) patient drug information (UpToDate)